Biogaya Shares Boosted by Analyst Price Target Upgrade

17 days ago

Khloe Mele

"Yeah, so that's not a company I've heard of before actually, but they make probiotic supplements for things like gut health and and immunity, things like that. This is of course something that is kind of all the rage at the moment, part of that broader wellness boom with everyone caring a lot about their protein intake and gut biome and and all of that. You haven't gotten it from Turkey over the past week. Yeah, [laughter] exactly. Um but Bay is up this morning after DNB Carnegie raised the price price target on that stock. Um and said that they could see margins recover quite a lot in 2026 and they expect a really strong sales growth uh for that and the end of this year for for the fourth quarter and then that momentum for earnings to continue to be really strong next year. So all around there's really good news for Baya and this vote of confidence has boosted those shares this morning."

Biogaya, a biotech firm that produces probiotic supplements, is receiving a boost after DNB Carnegie raised its price target on the stock. The analyst highlighted potential margin recovery in 2026 and strong sales growth in Q4, with continued earnings momentum expected into next year, offering a catalyst for further upside.

Related Stocks